ENXTPA:SANPharmaceuticals
Should Investors Reassess Sanofi After 14% Drop and Fresh Migraine Drug Approval?
Thinking about what to do with Sanofi stock? You are not alone, especially after a year that has tested the patience of even long-term holders. The share price is down about 14.4% for the year so far, and off by 18.5% over the last twelve months. Yet, sometimes it is exactly this kind of cooling-off period that gets value-focused investors interested.
Sanofi is the sort of company that rarely becomes a market darling overnight, but its underlying story has not faded. While some peers have...